CELC at a glance
Celcuity Inc. (CELC, SEC CIK 1603454) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on August 13, 2026, an 8-K current report on October 2, 2026 and Form 4 insider filings as recently as October 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 29 institutional investment managers tracked by SignalX reported holding Celcuity Inc. (CELC) shares worth $1.5 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by BAKER BROS. ADVISORS LP on July 14, 2026 of 261,368 shares at $102.50 per share.
- In the last 90 days, CELC insiders reported 0 open-market purchases ($0) and 2 open-market sales ($317.8M) on Form 4, a net sale of $317.8M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 2 sells
- Net −$317.8M
- 13F holders
- 29 funds
- $1.5B · −2 vs prior quarter
- Latest 8-K
- Sep 30, 2026
- Item 8.01 · Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue and YoY change not provided in the filing text
- Profitability margins and percentage changes not provided in the filing text
- Best-performing product: PIK3CA mutant triplet, median PFS 11.1 months and ORR 49%
- Commercial launch activities commenced after July 14, 2026 approval; shipments expected late third quarter 2026
- Near-term milestones: PIK3CA mutant sNDA submission planned third quarter 2026 and mCRPC data expected fourth quarter 2026
Risk Factors
- No material changes to risk factors disclosed in the 2025 10-K
- No newly triggered risk factor identified for the quarter ended June 30, 2026
- Carried-forward regulatory, legal, operational, competitive, and financial risks remain governed by the 2025 10-K disclosure
- Unknown or currently immaterial risks could materially adversely affect business, financial condition, or operating results
AI summary of the CELC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- REVTORPYK commercially available in the U.S. for eligible HR+/HER2- advanced breast cancer patients
- Indicated after progression following at least one metastatic-setting endocrine therapy line
Item 7.01: Regulation FD Disclosure
- REVTORPYK™ (gedatolisib) commercially available in the U.S. for eligible patients with HR+/HER2- locally advanced or metastatic breast cancer
- Initial indication targets patients without a PIK3CA mutation after progression on at least one metastatic endocrine-therapy line
Item EX-99.1: Item EX-99.1
- REVTORPYK became commercially available in the U.S. on September 30, 2026, initiating Celcuity’s first product launch
- FDA-approved for HR+/HER2- advanced breast cancer without detected PIK3CA mutation after at least one metastatic endocrine-therapy line
Item 8.01: Other Events
- sNDA submitted to FDA for REVTORPYK in HR+/HER2- advanced breast cancer with PIK3CA mutations
- Target population includes patients progressing after at least one endocrine-therapy line
Item 7.01: Regulation FD Disclosure
- Celcuity submitted an sNDA to the FDA for REVTORPYK™ in PIK3CA-mutated HR+/HER2- advanced breast cancer
- Target population: locally advanced or metastatic disease after at least one endocrine-therapy line
AI summaries of CELC 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CELC
Don't miss the next CELC filing
- Alerts as it files. A push when CELC files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CELC, by share count.
- Ask anything. An AI agent that reads every CELC filing and answers with sources.
CELC alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| GRYSKA DAVID W | A | Oct 1, 2026 | 893 | - |
| Laing Lance G. | A | Aug 14, 2026 | 20,000 | - |
| Laing Lance G. | A | Aug 14, 2026 | 10,000 | - |
| Hahne Vicky | A | Aug 14, 2026 | 10,000 | - |
| Sullivan Brian F. | A | Aug 14, 2026 | 80,000 | - |
| Sullivan Brian F. | A | Aug 14, 2026 | 120,000 | - |
| Hahne Vicky | A | Aug 14, 2026 | 16,000 | - |
| BAKER BROS. ADVISORS LP | Sell | Jul 14, 2026 | 261,368 | $102.50 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$66.2M | -$113.3M | -$172.2M |
| Net Income | -$63.8M | -$111.8M | -$177.0M |
| Balance Sheet | |||
| Total Assets | - | $245.1M | $466.6M |
| Equity | $139.8M | $115.6M | $100.6M |
| ROE | -45.6% | -96.7% | -176.1% |
| Per Share | |||
| EPS | $-2.69 | $-2.83 | $-3.79 |
| Cash Flow | |||
| Operating CF | -$53.8M | -$83.5M | -$153.3M |
| CapEx | $98K | $250K | $249K |
Source: XBRL data in Celcuity Inc. (CELC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate CELC share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 29 | $1.48B |
| Q1 2026 | 31 | $1.35B |
| Q4 2025 | 28 | $1.24B |
| Q3 2025 | 28 | $518.7M |
| Q2 2025 | 22 | $104.3M |
| Q1 2025 | 16 | $58.3M |
| Q4 2024 | 13 | $61.1M |
| Q3 2024 | 11 | $42.4M |
- Bank of America Corp+757.0K (+106%)
- FMR LLC (Fidelity)+512.6K (+1410%)
- State Street Corp+436.6K (+29%)
- BlackRock+307.3K (+11%)
- Franklin Resources+281.0K (+1650%)
- T. Rowe Price Group−254.0K (-20%)
- Ameriprise Financial−83.4K (-84%)
- Invesco Ltd−68.0K (-75%)
- Morgan Stanley−11.2K (-1%)
- AQR Capital Management−5.2K (-29%)
- Marex Group plc+2.6K
- Citadel Advisors LLC−131.9K
- Millennium Management−3.9K
- Mangrove Partners−2.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 178 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CELC filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 5, 2026 | - | - | - |
| 8-K | Oct 2, 2026 | - | - | - |
| 8-K | Sep 30, 2026 | - | Analysis | - |
| 8-K | Aug 26, 2026 | - | Analysis | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| SC 13G | Aug 11, 2026 | - | - | |
| 4 | Jul 16, 2026 | - | - | - |
| SC 13G | Jul 16, 2026 | - | - | |
| 8-K | Jul 15, 2026 | - | Analysis | - |
| 8-K | Jul 15, 2026 | - | Analysis | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 8-K | Jun 8, 2026 | - | Analysis | |
| 4 | Jun 4, 2026 | - | - | |
| 8-K | Jun 2, 2026 | - | Analysis |
Related Health Care companies
- CDNA · CareDx, Inc.Services-Medical Laboratories
- CSTL · CASTLE BIOSCIENCES INCServices-Medical Laboratories
- FTRE · Fortrea Holdings Inc.Services-Medical Laboratories
- FLGT · Fulgent Genetics, Inc.Services-Medical Laboratories
- GRAL · GRAIL, Inc.Services-Medical Laboratories
- GH · Guardant Health, Inc.Services-Medical Laboratories
- LH · LabcorpServices-Medical Laboratories
- NTRA · Natera IncServices-Medical Laboratories
CELC SEC filings: frequently asked questions
Are CELC insiders buying or selling?
In the last 90 days, Celcuity Inc. (CELC) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $317.8 million by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CELC stock?
As of June 30, 2026, the largest Celcuity Inc. (CELC) holders among the 13F filers tracked by SignalX were BlackRock ($315.8 million), State Street Corp ($204.6 million), Vanguard Capital Management LLC ($196.1 million), Bank of America Corp ($153.9 million), Morgan Stanley ($139.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did CELC report in its latest 8-K?
Celcuity Inc. (CELC) filed an 8-K on September 30, 2026 reporting Item 8.01 (Other Events) and Item 7.01 (Regulation FD Disclosure). REVTORPYK commercially available in the U.S. for eligible HR+/HER2- advanced breast cancer patients.
What are the latest CELC SEC filings?
Celcuity Inc. (CELC) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on August 13, 2026, an 8-K current report on October 2, 2026 and a Form 4 insider filing on October 5, 2026.
What is CELC's SEC CIK number?
Celcuity Inc. (CELC)'s SEC Central Index Key (CIK) is 1603454. EDGAR lists every CELC filing under that number.
Ask anything about CELC
The research agent reads CELC's filings, financials, insider trades and 13F holders, then answers with sources.